SCHEMBL3500950

SCHEMBL3500950

CC(=O)c1oc2cc(-c3ccc(Cl)cc3)ccc2c1C

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 2/20 0.60
ALDH1A1 P00352 3/20 0.43
KDM4E B2RXH2 2/20 0.43
KCNH2 Q12809 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
CA12 O43570 2/20 0.40
CA9 Q16790 2/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
THRB P10828 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
HSD17B3 P37058 1/20 0.39
HPGD P15428 1/20 0.39
HSD11B1 P28845 1/20 0.39
KMT2A Q03164 2/20 0.39
GPR35 Q9HC97 1/20 0.39
CNR1 P21554 1/20 0.39
CNR2 P34972 1/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3498475 0.88 MCL1 (0.78) MCL1ALDH1A1KDM4EKCNH2SMN1; SMN2
SCHEMBL3501203 0.87 MCL1 (0.58) MCL1ALDH1A1KDM4EKCNH2SMN1; SMN2
SCHEMBL3501204 0.87 MCL1 (0.58) MCL1ALDH1A1KDM4EKCNH2SMN1; SMN2
SCHEMBL3499722 0.82 HIF1A (0.55) MCL1ALDH1A1KDM4EKCNH2SMN1; SMN2
SCHEMBL3500040 0.79 MCL1 (0.53) MCL1KDM4ESMN1; SMN2LMNAMAPT
SCHEMBL11686876 0.78 MCL1 (0.77) MCL1ALDH1A1KDM4EKCNH2SMN1; SMN2
SCHEMBL3498799 0.78 MCL1 (0.51) MCL1KDM4ESMN1; SMN2LMNAMAPT
SCHEMBL3499014 0.77 MCL1 (0.78) MCL1ALDH1A1KDM4EKCNH2SMN1; SMN2
SCHEMBL3498156 0.76 MCL1 (0.49) MCL1ALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL3498797 0.76 MCL1 (0.46) MCL1ALDH1A1KDM4ESMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
EP-1849465-A1 AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR Takeda Pharmaceutical Company Limited (JP) 2007-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function GPR34, GPR4, GPR6 MCL1 3727/4885ALDH1A1 3047/4885KDM4E 2059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.